<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="4101">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04592549</url>
  </required_header>
  <id_info>
    <org_study_id>ADM03820-001</org_study_id>
    <nct_id>NCT04592549</nct_id>
  </id_info>
  <brief_title>This is a Phase 1 Clinical Trial to Evaluate the Safety, Pharmacokinetics, and Immunogenicity of ADM03820, a Monoclonal Antibody Cocktail Being Tested for the Treatment and Prevention of COVID-19</brief_title>
  <official_title>A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Dose Escalation Study to Evaluate the Safety, Pharmacokinetics, and Immunogenicity of ADM03820 in Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ology Bioservices</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Enabling Biotechnologies (EB)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Ology Bioservices</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      ADM03820 is indicated for the treatment and prevention of SARS-CoV-2 (COVID-19) in adults.&#xD;
      The primary purpose of this study is to assess the safety of ADM03820 in healthy male and&#xD;
      female subjects compared to placebo.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 4, 2020</start_date>
  <completion_date type="Anticipated">September 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The number of participants with Serious Adverse Events following administration of ADM03820 to the final visit</measure>
    <time_frame>540 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The number of participants with AEs from administration of ADM03820 to the final visit</measure>
    <time_frame>540 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The assessment of Peak Plasma Concentration (Cmax) for total antibodies of ADM03820 as measured by enzyme-linked immunosorbent assay (ELISA) methods designed for total monoclonal antibody in the Drug Product.</measure>
    <time_frame>540 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The assessment of Tmax for total antibodies of ADM03820 as measured by enzyme-linked immunosorbent assay (ELISA) methods designed for total monoclonal antibody in the Drug Product.</measure>
    <time_frame>540 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The assessment of the Area under the plasma concentration (AUC(0-t)) for total antibodies of ADM03820 as measured by enzyme-linked immunosorbent assay (ELISA) methods designed for total monoclonal antibody in the Drug Product.</measure>
    <time_frame>540 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess the anti-drug antibody levels</measure>
    <time_frame>540 days</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>SARS-CoV-2</condition>
  <arm_group>
    <arm_group_label>Low dose IM injection of active drug or placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects in cohort 1 will receive a low dose IM injection of either active drug or placebo.&#xD;
Cohort 1 will dose 8 subjects to active drug and 2 subject to placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High dose IM injection of active drug or placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects in cohort 2 will receive a high dose IM injection of either active drug or placebo.&#xD;
Cohort 2 will dose 8 subjects to active drug and 2 subject to placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low dose IV infusion of active drug or placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects in cohort 3 will receive a high dose IV infusion of either active drug or placebo.&#xD;
Cohort 3 will dose 8 subjects to active drug and 2 subject to placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High dose IV infusion of active drug or placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects in cohort 4 will receive a high dose IV infusion of either active drug or placebo.&#xD;
Cohort 4 will dose 8 subjects to active drug and 2 subject to placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ADM03820</intervention_name>
    <description>ADM03820 is a 1:1 mixture of two human IgG1 non-competitive binding anti-SARS-CoV-2 antibodies</description>
    <arm_group_label>High dose IM injection of active drug or placebo</arm_group_label>
    <arm_group_label>High dose IV infusion of active drug or placebo</arm_group_label>
    <arm_group_label>Low dose IM injection of active drug or placebo</arm_group_label>
    <arm_group_label>Low dose IV infusion of active drug or placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>High dose IM injection of active drug or placebo</arm_group_label>
    <arm_group_label>High dose IV infusion of active drug or placebo</arm_group_label>
    <arm_group_label>Low dose IM injection of active drug or placebo</arm_group_label>
    <arm_group_label>Low dose IV infusion of active drug or placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Informed consent understood and signed&#xD;
&#xD;
          2. Healthy male or healthy, non-pregnant, non-lactating female&#xD;
&#xD;
          3. Willingness to comply and be available for all protocol procedures for the duration of&#xD;
             the study&#xD;
&#xD;
          4. Between the ages of 18 and 55, inclusive on the day of dosing&#xD;
&#xD;
          5. Body Mass Index (BMI) of ≥18.5 and ≤35 kg/m2&#xD;
&#xD;
          6. Female subjects of childbearing potential must have a negative serum pregnancy test at&#xD;
             screening and negative urine pregnancy test on Day 1 prior to dosing.&#xD;
&#xD;
               -  Note: A woman is considered of childbearing potential unless post-menopausal (&gt;&#xD;
                  or = 1 year without menses without other known or suspected cause and&#xD;
                  appropriately elevated FSH) or surgically sterilized via bilateral oophorectomy&#xD;
                  or hysterectomy&#xD;
&#xD;
          7. Females of childbearing potential and males agree to use acceptable contraception for&#xD;
             the duration of the study&#xD;
&#xD;
               -  Note: These include progestin implants, intrauterine devices (IUDs), surgical&#xD;
                  (hysterectomy or tubal ligation; vasectomy) or abstinence. Use of methods such as&#xD;
                  progestin injectables, combined oral hormonal contraceptives, condoms, and&#xD;
                  diaphragms will not be acceptable when used alone, but they could be considered,&#xD;
                  if used in combination with another method (for example, a female using combined&#xD;
                  oral contraceptives if her male partner is sterile, or if she and her non-sterile&#xD;
                  male partner use a double-barrier method), after consultation with the Ology&#xD;
                  Bioservices MM. All males will be required to use a barrier method (condoms) for&#xD;
                  the duration of the study&#xD;
&#xD;
          8. Screening laboratory tests are within normal ranges or outside the normal ranges and&#xD;
             considered not clinically significant by the Principal Investigator&#xD;
&#xD;
               1. If urinalysis by dipstick is abnormal, a complete urinalysis with microscopic&#xD;
                  evaluation will be performed and the results will supersede the results of the&#xD;
                  dipstick for blood, glucose, and protein.&#xD;
&#xD;
               2. Menstruating females failing inclusion criteria due to a positive blood on urine&#xD;
                  test may be retested following cessation of menses.&#xD;
&#xD;
               3. Other laboratory values that are outside the range of eligibility but are thought&#xD;
                  to be due to an acute condition or collection or laboratory error may be repeated&#xD;
                  once.&#xD;
&#xD;
          9. The urine drug screen is negative&#xD;
&#xD;
         10. Breathalyzer test is negative and subject agrees to abstain from alcohol consumption&#xD;
             for a period of 2 days prior to dosing and 2 days prior to any study visit.&#xD;
&#xD;
         11. Agree to minimize risk of SARS-CoV-2 infection.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History of chronic medical condition that would either interfere with the accurate&#xD;
             assessment of the objectives of the study or increase the risk profile of the subject.&#xD;
&#xD;
          2. Subjects with cardiovascular disease&#xD;
&#xD;
          3. Subjects with diabetes&#xD;
&#xD;
          4. Subjects with pulmonary diseases such as COPD or asthma&#xD;
&#xD;
          5. History of severe allergic reactions of any type to medications, bee stings, food, or&#xD;
             environmental factors or hypersensitivity or reaction to immunoglobins.&#xD;
&#xD;
          6. A marked baseline prolongation of QT/QTc interval (e.g., repeated demonstration of a&#xD;
             QTc interval &gt;450 milliseconds)&#xD;
&#xD;
          7. Clinically significant abnormal electrocardiogram at screening.&#xD;
&#xD;
               -  Note: Clinically significant abnormal ECG results include but not limited to:&#xD;
&#xD;
             complete left or right bundle branch block; other ventricular conduction block; 2nd&#xD;
             degree or 3rd degree atrioventricular (AV) block; sustained ventricular arrhythmia;&#xD;
             sustained atrial arrhythmia; two Premature Ventricular Contractions in a row; pattern&#xD;
             of ST elevation felt consistent with cardiac ischemia; or any condition deemed&#xD;
             clinically significant by a study investigator&#xD;
&#xD;
               -  Incomplete right bundle branch block is not exclusionary if there are no abnormal&#xD;
                  ECG findings and there is no clinical history or evidence on physical examination&#xD;
                  to indicate cardiac disease.&#xD;
&#xD;
          8. Positive serology results for HIV, HBsAg, or HCV antibodies&#xD;
&#xD;
          9. Febrile illness with temperature ≥38°C within 7 days of dosing&#xD;
&#xD;
         10. Female subject who is pregnant or breastfeeding&#xD;
&#xD;
         11. Donated blood within 56 days of enrollment&#xD;
&#xD;
         12. Known allergic reactions to any of the study product components present in the&#xD;
             formulation or in the processing, as listed in the Investigator Brochure&#xD;
&#xD;
         13. Treatment with another investigational drug within 28 days of dosing&#xD;
&#xD;
         14. Treatment with a monoclonal antibody within 3 months of enrollment&#xD;
&#xD;
         15. Positive serology results for SARS-CoV-2 antibodies.&#xD;
&#xD;
         16. Positive results from a reverse transcriptase polymerase chain reaction (RT PCR) test&#xD;
             for SARS CoV 2&#xD;
&#xD;
         17. Receipt of antibody (e.g. TIG, VZIG, IVIG, IM gamma globulin) or blood transfusion&#xD;
             within 6 months or within 5 half-lives of the specific product given&#xD;
&#xD;
         18. Active drug or alcohol use disorder or dependence that, in the opinion of the&#xD;
             investigator, would interfere with adherence to study requirements&#xD;
&#xD;
         19. Use of H1 antihistamines or beta-blockers within 5 days of dosing&#xD;
&#xD;
         20. Use of any prohibited medication within 28 days prior to screening or planned use&#xD;
             during the study period&#xD;
&#xD;
               -  Note: Prohibited medications include immunosuppressives (except Nonsteroidal&#xD;
                  Anti-Inflammatory Drugs [NSAIDS]); immune modulators; oral corticosteroids&#xD;
                  (topical/intranasal steroids are acceptable); anti-neoplastic agents&#xD;
&#xD;
         21. Any specific condition that in the judgment of the investigator precludes&#xD;
             participation because it could affect subject safety&#xD;
&#xD;
         22. Plans to enroll or is already enrolled in another clinical trial that could interfere&#xD;
             with safety assessment of the investigational product at any time during the study&#xD;
             period&#xD;
&#xD;
               -  Note: Includes trials that have a study intervention such as a drug, biologic, or&#xD;
                  device&#xD;
&#xD;
         23. Is a study site employee or staff&#xD;
&#xD;
               -  Note: Site employees or staff include the PIs and sub-investigators or staff who&#xD;
                  are supervised by the PI or Sub-Investigators&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Angie Kimbler</last_name>
    <phone>386-418-8751</phone>
    <email>angie.kimbler@ologybio.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>PMG Research of Winston-Salem, LLC</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jonathan P Wilson, DO</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ICON Early Phase Services, LLC</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78209</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Cassandra C Key, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>October 12, 2020</study_first_submitted>
  <study_first_submitted_qc>October 16, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 19, 2020</study_first_posted>
  <last_update_submitted>December 8, 2020</last_update_submitted>
  <last_update_submitted_qc>December 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

